Clinical Trial Update: LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma [Phase 2]

View source ↗

Summary

This Phase 2 trial of LGX818 in combination with multiple targeted agents in advanced BRAF-mutant melanoma was terminated, and results were posted on January 9,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BGJ398 (BGJ398)
• BKM120 (Buparlisib)
• INC280
• LEE011 (ribociclib)
• LGX818 (encorafenib)
• MEK162 (binimetinib)

Snippet

Sponsor: Array BioPharma | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2017-01-09